Are the new weight loss medications the treatment the food industry needs?
Background New weight loss medications, including newer incretin mimetics such as GLP-1 receptor agonists, are likely to revolutionise the treatment of obesity but their effects should be understood not only clinically but also within the food system. Main Body Using the National Institute of Health Body Weight Planner and weight loss data from clinical trials of semaglutide and tirzepatide, we estimated the average daily energy intake before treatment, during the initial weight loss phase, and with long-term sustained treatment. Compared with the average daily energy intake of 2,666 kcal/day before treatment initiation, these treatments are associated with an 18–26% lower energy intake during the initial weight loss phase and a persistent 10–16% lower energy intake thereafter if treatment is sustained. Conclusion This extent of energy intake reduction is small enough to avoid clinical concerns about population-level malnutrition but large enough to alter food demand and underscores the need for the food system to adapt.
Authors
- Dimitrios A. Koutoukidis (ORCID: https://orcid.org/0000-0002-1955-7234)
- Susan A. Jebb
Institutions
- University of Oxford (GB)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1186/s12916-026-05329-2
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research